Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

AIMS: To evaluate potential differences between PF‐05280586 and rituximab sourced from the European Union (rituximab‐EU) and USA (rituximab‐US) in clinical response (Disease Activity Score in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Clin Pharmacol
Autori principali: Williams, Jason H., Hutmacher, Matthew M., Zierhut, Matthew L., Becker, Jean‐Claude, Gumbiner, Barry, Spencer‐Green, George, Melia, Lisa A., Liao, Kai‐Hsin, Suster, Matthew, Yin, Donghua, Li, Ruifeng, Meng, Xu
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Pharmacokinetic Dynamic Relationships
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5099556/
https://ncbi.nlm.nih.gov/pubmed/27530379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13094
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi